531 related articles for article (PubMed ID: 12120256)
1. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
Capdeville R; Buchdunger E; Zimmermann J; Matter A
Nat Rev Drug Discov; 2002 Jul; 1(7):493-502. PubMed ID: 12120256
[TBL] [Abstract][Full Text] [Related]
2. Imatinib: a targeted clinical drug development.
Capdeville R; Silberman S
Semin Hematol; 2003 Apr; 40(2 Suppl 2):15-20. PubMed ID: 12783370
[TBL] [Abstract][Full Text] [Related]
3. [Imatinib].
Urabe A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
[TBL] [Abstract][Full Text] [Related]
4. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
5. [Imatinib--a new perspective in the treatment of tumors].
Klener P; Klamová H
Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
[TBL] [Abstract][Full Text] [Related]
6. Imatinib as a paradigm of targeted therapies.
Druker BJ
Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
[TBL] [Abstract][Full Text] [Related]
7. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
8. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
9. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
10. The biology of signal transduction inhibition: basic science to novel therapies.
Griffin J
Semin Oncol; 2001 Oct; 28(5 Suppl 17):3-8. PubMed ID: 11740801
[TBL] [Abstract][Full Text] [Related]
11. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Goldman JM; Melo JV
N Engl J Med; 2001 Apr; 344(14):1084-6. PubMed ID: 11287980
[No Abstract] [Full Text] [Related]
12. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ
Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
[No Abstract] [Full Text] [Related]
13. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
14. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
La Rosée P; Corbin AS; Stoffregen EP; Deininger MW; Druker BJ
Cancer Res; 2002 Dec; 62(24):7149-53. PubMed ID: 12499247
[TBL] [Abstract][Full Text] [Related]
15. [STI571: a summary of targeted therapy].
Czyz M; Jakubowska J
Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
[TBL] [Abstract][Full Text] [Related]
16. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
[TBL] [Abstract][Full Text] [Related]
17. [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
Guilhot F
Bull Cancer; 2001 Jul; 88(7):659-60. PubMed ID: 11495817
[No Abstract] [Full Text] [Related]
18. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
19. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
20. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
